JAK Inhibitor Dose TAPering Strategy Study

Recruiting now · Phase 4

Conditions studied: Rheumatoid Arthritis (RA

In brief

This study aims to assess the feasibility of tapering JAK inhibitors in rheumatoid arthritis patients in low disease activity by comparing a group of patients tapering the JAK inhibitor dosage to a group of patients continuing the full-dose. Participants will: * Either take 1. JAK inhibitor dose-tapering strategy. 2. JAK inhibitor continuous therapy strategy. * Visit the clinic once every 3 months for checkups and tests * Keep a diary of their treatment intake and symptoms

Key facts

Study ID
NCT06687551
Run by
University Hospital, Toulouse
People needed
308
Starts
2025-06-06
Expected to finish
2029-04-01
Last updated by the study team
2026-08-07

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.